AUTL · Autolus Therapeutics plc · Executive Compensation
Market Cap
$493.73M
Shares
266.16M
Volume · Oct 1
1.46M
Avg daily vol (3M)
2.05M
Named-executive compensation from the company's DEF 14A proxy statements — salary, bonus, stock and option awards, non-equity incentive, and the company-reported total per executive per fiscal year, exactly as disclosed in the Summary Compensation Table.
No Compensation Data
No Summary Compensation Table has been imported from this company's proxy statements yet.
Executive changes
| Person | Role | Change | Filed |
|---|---|---|---|
| Ryan Richardson | Class I director | Appointed | 2025-12-02 |
| Miranda Neville | Chief Technical Officer | Appointed | 2025-11-12 |
| Patrick McIlvenny | Principal Accounting Officer | Appointed | 2025-11-12 |
| Rob Dolski | principal accounting officer | Appointed | 2025-04-03 |
| Michael W. Bonney | Class II director | Appointed | 2024-04-01 |
| Ravi M. Rao | Class I director | Appointed | 2024-04-01 |
| Michael W. Bonney | Chair of the Board | Appointed | 2024-04-01 |
| John Johnson | Director | Resigned | 2024-04-01 |
| Robert (“Bob”) W. Azelby | Class II director | Appointed | 2024-01-10 |
| Elisabeth ("Lis") Leiderman, M.D. | Class II director | Appointed | 2023-12-22 |
| Kapil Dhingra, M.D. | member of the Board of Directors | Resigned | 2023-12-22 |